Literature DB >> 26600880

Evaluation of neutrophil-to-lymphocyte ratio prior to prostate biopsy to predict biopsy histology: Results of 1836 patients.

Mehmet Ilker Gokce1, Nurullah Hamidi1, Evren Suer1, Semih Tangal2, Adil Huseynov1, Arif Ibiş1.   

Abstract

INTRODUCTION: We evaluate the role of NLR prior to prostate biopsy to predict biopsy histology and Gleason score in patients with prostate cancer.
METHODS: In this retrospective study, we evaluated data of patients underwent prostate biopsy between May 2005 and March 2015. We collected the following data: age, prostate-specific antigen (PSA), biopsy histology, Gleason score (GS) in prostate cancer patients, neutrophil counts, and lymphocyte counts. Patients were grouped as benign prostatic hyperplasia (BPH), prostate cancer, and prostatitis. The Chi square test was used to compare categorical variables and analysis of variance (ANOVA) was applied for continuous variables.
RESULTS: Data of 1836 patients were investigated. The mean age, total PSA and neutrophil-lymphocyte ratio (NLR) of the population were 66.8 ± 8.17 years, 9.38 ± 4.7 ng/dL, and 3.11 ± 1.71, respectively. Patients were divided as follows: 625 in the group with BPH history, 600 in the prostatitis group, and 611 in the prostate cancer histology group. The mean NLR of the prostatitis group was higher compared to the prostate cancer and BPH groups (p = 0.0001). The mean NLR of the prostate cancer group was significantly higher compared to the BPH group (p = 0.002). The GS 8-10 group had a significantly higher mean NLR compared to GS 5-6 (3.64 vs. 2.54, p = 0.0001) and GS 7 (3.64 vs. 2.58, p = 0.0001) patients.
CONCLUSIONS: NLR was found to differ with regard to histology of prostate biopsy and higher GS was associated with higher NLR in patients with prostate cancer. However prostatitis prevents the use of NLR in predicting prostate cancer before a prostate biopsy. Also, the retrospective nature and lack of multivariate analysis in this study somewhat limits the relevance of these results.

Entities:  

Year:  2015        PMID: 26600880      PMCID: PMC4639422          DOI: 10.5489/cuaj.3091

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  19 in total

1.  Cancer incidence and mortality in Europe, 2004.

Authors:  P Boyle; J Ferlay
Journal:  Ann Oncol       Date:  2005-02-17       Impact factor: 32.976

2.  Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory.

Authors:  Melina Arnold; Henrike E Karim-Kos; Jan Willem Coebergh; Graham Byrnes; Ahti Antilla; Jacques Ferlay; Andrew G Renehan; David Forman; Isabelle Soerjomataram
Journal:  Eur J Cancer       Date:  2013-10-08       Impact factor: 9.162

Review 3.  Inflammation in prostate carcinogenesis.

Authors:  Angelo M De Marzo; Elizabeth A Platz; Siobhan Sutcliffe; Jianfeng Xu; Henrik Grönberg; Charles G Drake; Yasutomo Nakai; William B Isaacs; William G Nelson
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

4.  Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients.

Authors:  Tanja Langsenlehner; Eva-Maria Thurner; Sabine Krenn-Pilko; Uwe Langsenlehner; Tatjana Stojakovic; Armin Gerger; Martin Pichler
Journal:  World J Urol       Date:  2015-01-24       Impact factor: 4.226

5.  Lymphocyte counts independently predict overall survival in advanced cancer patients: a biomarker for IL-2 immunotherapy.

Authors:  Luca A Fumagalli; Jan Vinke; Wilco Hoff; Ellen Ypma; Ferdinando Brivio; Angelo Nespoli
Journal:  J Immunother       Date:  2003 Sep-Oct       Impact factor: 4.456

6.  Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001-2008 National Health and Nutrition Examination Survey.

Authors:  Alicia C McDonald; Manish A Vira; Adriana C Vidal; Wenqi Gan; Stephen J Freedland; Emanuela Taioli
Journal:  Prostate       Date:  2014-01-16       Impact factor: 4.104

Review 7.  The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer.

Authors:  Graeme J K Guthrie; Kellie A Charles; Campbell S D Roxburgh; Paul G Horgan; Donald C McMillan; Stephen J Clarke
Journal:  Crit Rev Oncol Hematol       Date:  2013-04-17       Impact factor: 6.312

8.  C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.

Authors:  Tomasz M Beer; Alshad S Lalani; Stella Lee; Motomi Mori; Kristine M Eilers; John G Curd; W David Henner; Christopher W Ryan; Peter Venner; J Dean Ruether; Kim N Chi
Journal:  Cancer       Date:  2008-06       Impact factor: 6.860

Review 9.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

Review 10.  A systematic review of the association between circulating concentrations of C reactive protein and cancer.

Authors:  Katriina Heikkilä; Shah Ebrahim; Debbie A Lawlor
Journal:  J Epidemiol Community Health       Date:  2007-09       Impact factor: 3.710

View more
  13 in total

1.  The neutrophil-to-lymphocyte ratio in clinical practice.

Authors:  Ali Gürağaç; Zafer Demirer
Journal:  Can Urol Assoc J       Date:  2016 Mar-Apr       Impact factor: 1.862

2.  Author reply: The neutrophil-to-lymphocyte ratio in clinical practice.

Authors:  Mehmet Ilker Gokce; Nurullah Hamidi; Evren Suer; Semih Tangal; Adil Huseynov; Arif Ibiş
Journal:  Can Urol Assoc J       Date:  2016 Mar-Apr       Impact factor: 1.862

3.  Role of neutrophil-to-lymphocyte ratio in prediction of Gleason score upgrading and disease upstaging in low-risk prostate cancer patients eligible for active surveillance.

Authors:  Mehmet Ilker Gokce; Semih Tangal; Nurullah Hamidi; Evren Suer; Muhammed Arif Ibis; Yasar Beduk
Journal:  Can Urol Assoc J       Date:  2016-11-10       Impact factor: 1.862

4.  Validation of the Effectiveness of Neutrophil-to-lymphocyte Ratio (NLR) as a Predictive Factor in Patients Undergoing Prostate Biopsy With Prostate Specific Antigen (PSA) Between 4.0 and 10.0 ng/ml.

Authors:  Hiroshi Masuda; Kosuke Mikami; Kotaro Otsuka; Kyokusin Hou; Takahito Suyama; Kazuhiro Araki; Satoko Kojima; Yukio Naya
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

5.  Association between systemic inflammation and serum prostate-specific antigen in a healthy Korean population.

Authors:  Jonghyun Yun; Hyunyoung Lee; Wonjae Yang
Journal:  Turk J Urol       Date:  2017-08-01

6.  Predictive value of preoperative neutrophil-to-lymphocyte ratio in localized prostate cancer: results from a surgical series at a high-volume institution.

Authors:  Carlo A Bravi; Giuseppe Rosiello; Giuseppe Fallara; Emily Vertosick; Amy Tin; Daniel Sjoberg; Marco Bianchi; Elio Mazzone; Alberto Martini; Paolo Dell'oglio; Armando Stabile; Giorgio Gandaglia; Nicola Fossati; Alberto Briganti; Francesco Montorsi; Andrew Vickers
Journal:  Minerva Urol Nephrol       Date:  2020-02-19

Review 7.  Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Localized and Advanced Prostate Cancer: A Systematic Review and Meta-Analysis.

Authors:  Lu Tang; Xintao Li; Baojun Wang; Guoxiong Luo; Liangyou Gu; Luyao Chen; Kan Liu; Yu Gao; Xu Zhang
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

8.  Predictive value of neutrophil-to-lymphocyte ratio in diagnosis of prostate cancer among men who underwent template-guided prostate biopsy: A STROBE-compliant study.

Authors:  Tian-Bao Huang; Shi-Yu Mao; Sheng-Ming Lu; Jun-Jie Yu; Yang Luan; Xiao Gu; Hao Liu; Guang-Chen Zhou; Xue-Fei Ding
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

9.  The values of neutrophil-lymphocyte ratio and/or prostate-specific antigen in discriminating real Gleason score ≥ 7 prostate cancer from group of biopsy-based Gleason score ≤ 6.

Authors:  Hanfeng Wang; Liangyou Gu; Yongjie Wu; Dan Feng; Junyao Duan; Xiaocong Wang; Yong Huang; Shengpan Wu; Jianwen Chen; Guangda Luo; Xu Zhang
Journal:  BMC Cancer       Date:  2017-09-06       Impact factor: 4.430

10.  Prognostic Value of Neutrophil to Lymphocyte Ratio on Pathologic Findings of Transrectal Ultrasonography Guided Biopsy of Prostate.

Authors:  Iraj Khosropanah; Sadeq Rostami; Zhoobin Heidari Bateni; Mojtaba Teimoori; Darya Khosrovpanah
Journal:  Iran J Pathol       Date:  2018-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.